Statins: inhibitors of HMGCOA REDUCTASE
DOI:
https://doi.org/10.32385/rpmgf.v17i2.9831Keywords:
3-hydroxy-3methylglutaryl-coenzyme A reductase inhibitors, Statins, Hypercholesterolemia, Dyslipidemia, Primary and secondary prevention of coronary artery diseaseAbstract
This article is a short review of the pharmacological profile of the 3-hydroxy-3methylglutaryl-coenzyme A reductase inhibitors - also known as statins - marketed in Portugal. The mechanism of action, the pharmacodynamic activities on serum lipids (LDL-cholesterol, HDL-cholesterol and tryglicerides) according to different doses, the absorption and metabolism, the safety and drug-drug interactions profiles are described. Initial therapeutic doses, as well as recommendations for dose titrations, are also presented, along with a brief presentation of other potential pharmacological effects of statin drugs, beyond serum lipid levels modifications.Downloads
Downloads
Published
Issue
Section
License
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
